05:33 AM EDT, 09/11/2026 (MT Newswires) -- RTW Biotech Opportunities (RTW.L) said Friday it invested an additional $4.1 million in Encoded Therapeutics as part of the latter's $275 million Series F financing. The proceeds will support pivotal and expansion studies of Encoded's gene therapy candidate ETX101 for the treatment of Dravet syndrome, as well as manufacturing scale-up and development of its broader neurology pipeline. The London-listed investment company first invested in Encoded in 2020.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.